# Combination Immunotherapy in Rare Cancers Under InvesTigation

> **NCT04969887** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Olivia Newton-John Cancer Research Institute** · enrollment: 240 (actual)

## Conditions studied

- Advanced Biliary Tract Cancer
- Neuroendocrine Tumors
- Female Reproductive System Neoplasm
- MSI-H Solid Malignant Tumor

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04969887
- **Lead sponsor:** Olivia Newton-John Cancer Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-03
- **Primary completion:** 2025-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04969887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04969887, "Combination Immunotherapy in Rare Cancers Under InvesTigation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04969887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*